Virtus Inspire Ventures

Design Pharma has a unique suite of proprietary technologies that enable the discovery and biosynthetic production of drug candidates. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States.

Apexigen is a clinical-stage biopharmaceutical company developing antibody therapeutics for the treatment of cancer. It specializes in new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.

Apexigen is a clinical-stage biopharmaceutical company developing antibody therapeutics for the treatment of cancer. It specializes in new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.

Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.

Gordian Surgical was founded at the end of 2012 and operates within the framework of the Misgav Venture Accelerator, part of The Trendlines Group. The company has three U.S. patents that cover the laparoscopic trocar and fascial closure systems and methods and suture anchor deployment systems and methods. Gordian has developed an initial prototype and will start preclinical trials in mid-2013.

Gordian Surgical was founded at the end of 2012 and operates within the framework of the Misgav Venture Accelerator, part of The Trendlines Group. The company has three U.S. patents that cover the laparoscopic trocar and fascial closure systems and methods and suture anchor deployment systems and methods. Gordian has developed an initial prototype and will start preclinical trials in mid-2013.